Argatroban

Argatroban

Clinical data
Routes of administration	intravenous
ATC code	B01AE03 (WHO)
Pharmacokinetic data
Bioavailability	100% (intravenous)
Protein binding	54%
Metabolism	hepatic
Elimination half-life	39 and 51 minutes
Identifiers
IUPAC name (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2- [[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl] sulfonylamino]pentanoyl]-4-methyl-piperidine-2- carboxylic acid
CAS Number	74863-84-6
PubChem CID	152951
DrugBank	APRD00105
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H36N6O5S
Molar mass	508.635 g/mol

WikiDoc Resources for Argatroban
Articles
Most recent articles on Argatroban Most cited articles on Argatroban Review articles on Argatroban Articles on Argatroban in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Argatroban Images of Argatroban Photos of Argatroban Podcasts & MP3s on Argatroban Videos on Argatroban
Evidence Based Medicine
Cochrane Collaboration on Argatroban Bandolier on Argatroban TRIP on Argatroban
Clinical Trials
Ongoing Trials on Argatroban at Clinical Trials.gov Trial results on Argatroban Clinical Trials on Argatroban at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Argatroban NICE Guidance on Argatroban NHS PRODIGY Guidance FDA on Argatroban CDC on Argatroban
Books
Books on Argatroban
News
Argatroban in the news Be alerted to news on Argatroban News trends on Argatroban
Commentary
Blogs on Argatroban
Definitions
Definitions of Argatroban
Patient Resources / Community
Patient resources on Argatroban Discussion groups on Argatroban Patient Handouts on Argatroban Directions to Hospitals Treating Argatroban Risk calculators and risk factors for Argatroban
Healthcare Provider Resources
Symptoms of Argatroban Causes & Risk Factors for Argatroban Diagnostic studies for Argatroban Treatment of Argatroban
Continuing Medical Education (CME)
CME Programs on Argatroban
International
Argatroban en Espanol Argatroban en Francais
Business
Argatroban in the Marketplace Patents on Argatroban
Experimental / Informatics
List of terms related to Argatroban

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. In 2002, it was approved for use during percutaneous coronary interventions in patients who have or at risk for developing HIT.

Argatroban is given intravenously. Argatroban is metabolized in the liver and has a half life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).

It is manufactured by GlaxoSmithKline.

Reference

• Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. PMID 16148288.

External links

• GlaxoSmithKline's website on argatroban